|
|
|
|
|
|
|
10.04.26 - 09:30
|
China healthcare stocks outgain Hong Kong market as Middle East roils global investments (SCMP)
|
|
|
China's healthcare sector has been drawing offshore capital to Hong Kong-listed stocks as investors look for safe havens amid global volatility in commodities.
The Hang Seng Healthcare Index, tracking some of China's most innovative pharmaceutical companies including Akeso and Innovent Biologics, has surged about 13 per cent since March 23, outpacing the benchmark Hang Seng Index's about 6 per cent gain over the same period.
“Although the Middle East conflict has created a lot of uncertainty and......
|
|
|
10.04.26 - 08:48
|
Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026 (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate at Nordic Health Summit Japan, April 23–24, 2026 in Tokyo, Japan, and ChinaBio Partnering Forum, April 28–29, 2026 in Shanghai, China. The events provide strategic platforms to advance partnering discussions with potential pharmaceutical partners and strengthen Cereno Scientific's growing presence in key Asian markets aiming to maximize the value of its HDAC inhibitor...
|
|
|
10.04.26 - 02:03
|
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases (PR Newswire)
|
|
|
SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and......
|
|
|
|
|
09.04.26 - 15:36
|
Tender Offer for Yomeishu Seizo Completed (Nippon)
|
|
|
Tokyo, April 9 (Jiji Press)--Japan's Yomeishu Seizo Co. said Thursday that Reno, an investment firm linked to Japanese activist investor Yoshiaki Murakami, has successfully completed its tender offer for the medical liqueur maker. The move is part of a deal to sell part of Yomeishu Seizo's operations to Japanese herbal medicine maker Tsumura & Co. Related procedures are expected to be comple......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.04.26 - 12:12
|
EverSea Medicines to acquire Hasten Biopharmaceuticals (PBR)
|
|
|
The acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in
The post EverSea Medicines to acquire Hasten Biopharmaceuticals appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
09.04.26 - 02:36
|
China biotech flow picks up as Everest seals US$250 million deal (SCMP)
|
|
|
China's biopharmaceutical sector is seeing an uptick in deal-making, with sovereign wealth funds from Singapore and the United Arab Emirates joining Chinese state-backed investors to back next-generation drug developers.
Shanghai-based Everest Medicines agreed to spend US$250 million to acquire a Singapore company holding rights to 14 chronic-disease treatments across the Asia-Pacific region, according to a stock exchange filing on Wednesday.
Its Singapore unit will acquire 100 per cent of......
|
|
|
09.04.26 - 02:03
|
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 (GlobeNewswire EN)
|
|
|
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California....
|
|
|
09.04.26 - 01:36
|
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 09 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
